Notice: You have clicked on a link which leaves Fresenius Kabi’s website and you will be redirected to a third-party website. Fresenius Kabi makes no representations nor has any supervision or control over the quality, content, reliability, or security of the third-party website, nor shall Fresenius Kabi be liable for its use.
We’re pioneering clinical nutrition with innovations that nourish
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Our products are used to help care for critically ill and chronically ill patients in hospitals, long-term care facilities, and at home.
Caring for the COVID-19 patient
Optimal nutritional support is critical for COVID-19 patients in the ICU, which is why experts recommend considering alternative lipid injectable emulsions (ILEs) for this patient population.1 As an early pioneer in alternative mixed lipid emulsions, Fresenius Kabi is expanding clinical nutrition options for critically ill patients.
A tireless dedication to driving advancements in lifesaving medicines and technologies has led to many firsts in the field, keeping Fresenius Kabi at the forefront of PN. We are proud to be the U.S. lipid injectable emulsion (ILE) market leader.2
Introduced the first lipid PN product for adults in more than 40 years
Pioneered the use of fish oil and omega-3s in PN products
Brought the benefits of alternative lipid emulsions to market
Developed the only pediatric lipid ILE product for PN-associated cholestasis (PNAC) in the U.S.
Developed the first and only three-chamber bag for adult PN in the U.S.
References: 1. Martindale R, Patel J, Taylor B, et al. Nutrition therapy in critically ill patients with coronavirus disease 2019. JPEN J Parenter Enteral Nutr. 2020;44(7):1174-1184. 2. Data on File; 8/1/20; calculation includes: all ILEs approved in the US.